Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials - PubMed (original) (raw)

Meta-Analysis

Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials

Giuseppe Grosso et al. PLoS One. 2014.

Abstract

Background: Despite omega-3 polyunsaturated fatty acids (PUFA) supplementation in depressed patients have been suggested to improve depressive symptomatology, previous findings are not univocal.

Objectives: To conduct an updated meta-analysis of randomized controlled trials (RCTs) of omega-3 PUFA treatment of depressive disorders, taking into account the clinical differences among patients included in the studies.

Methods: A search on MEDLINE, EMBASE, PsycInfo, and the Cochrane Database of RCTs using omega-3 PUFA on patients with depressive symptoms published up to August 2013 was performed. Standardized mean difference in clinical measure of depression severity was primary outcome. Type of omega-3 used (particularly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) and omega-3 as mono- or adjuvant therapy was also examined. Meta-regression analyses assessed the effects of study size, baseline depression severity, trial duration, dose of omega-3, and age of patients.

Results: Meta-analysis of 11 and 8 trials conducted respectively on patients with a DSM-defined diagnosis of major depressive disorder (MDD) and patients with depressive symptomatology but no diagnosis of MDD demonstrated significant clinical benefit of omega-3 PUFA treatment compared to placebo (standardized difference in random-effects model 0.56 SD [95% CI: 0.20, 0.92] and 0.22 SD [95% CI: 0.01, 0.43], respectively; pooled analysis was 0.38 SD [95% CI: 0.18, 0.59]). Use of mainly EPA within the preparation, rather than DHA, influenced final clinical efficacy. Significant clinical efficacy had the use of omega-3 PUFA as adjuvant rather than mono-therapy. No relation between efficacy and study size, baseline depression severity, trial duration, age of patients, and study quality was found. Omega-3 PUFA resulted effective in RCTs on patients with bipolar disorder, whereas no evidence was found for those exploring their efficacy on depressive symptoms in young populations, perinatal depression, primary disease other than depression and healthy subjects.

Conclusions: The use of omega-3 PUFA is effective in patients with diagnosis of MDD and on depressive patients without diagnosis of MDD.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Cited by

Role of Omega-3 Fatty Acids in the Etiology, Treatment, and Prevention of Depression: Current Status and Future Directions.
McNamara RK. McNamara RK. J Nutr Intermed Metab. 2016 Sep;5:96-106. doi: 10.1016/j.jnim.2016.04.004. Epub 2016 May 4. J Nutr Intermed Metab. 2016. PMID: 27766299 Free PMC article.
Omega-3 Polyunsaturated Fatty Acids in Depression.
Serefko A, Jach ME, Pietraszuk M, Świąder M, Świąder K, Szopa A. Serefko A, et al. Int J Mol Sci. 2024 Aug 8;25(16):8675. doi: 10.3390/ijms25168675. Int J Mol Sci. 2024. PMID: 39201362 Free PMC article. Review.
An observational study of acupuncture and complementary treatments for major depression: Case series from a preliminary study of proposed collaborative care model.
Tamayo SM, Wei TH, Chen LY, Ho WC, Ton G, Lee YC. Tamayo SM, et al. J Tradit Complement Med. 2022 Mar 26;12(5):499-504. doi: 10.1016/j.jtcme.2022.03.002. eCollection 2022 Sep. J Tradit Complement Med. 2022. PMID: 36081817 Free PMC article.
Long-chain omega-3 fatty acids in aneurysmal subarachnoid hemorrhage: A randomized pilot trial of pharmaconutrition.
Saito G, Zapata R, Rivera R, Zambrano H, Rojas D, Acevedo H, Ravera F, Mosquera J, Vásquez JE, Mura J. Saito G, et al. Surg Neurol Int. 2017 Dec 27;8:304. doi: 10.4103/sni.sni_266_17. eCollection 2017. Surg Neurol Int. 2017. PMID: 29404191 Free PMC article.
The Effect of DHA Supplementation on Cognition in Patients with Bipolar Disorder: An Exploratory Randomized Control Trial.
Ciappolino V, DelVecchio G, Prunas C, Andreella A, Finos L, Caletti E, Siri F, Mazzocchi A, Botturi A, Turolo S, Agostoni C, Brambilla P. Ciappolino V, et al. Nutrients. 2020 Mar 6;12(3):708. doi: 10.3390/nu12030708. Nutrients. 2020. PMID: 32155883 Free PMC article. Clinical Trial.

References

1. Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B (2012) Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 5: 808–818. - PubMed
1. Grosso G, Galvano F, Marventano S, Malaguarnera M, Bucolo C, et al. (2014) Omega-3 Fatty Acids and Depression: Scientific evidence and Biological Mechanisms. Oxid Med Cell Longev 2014: 313570. - PMC - PubMed
1. Machado-Vieira R, Mallinger AG (2012) Abnormal function of monoamine oxidase-A in comorbid major depressive disorder and cardiovascular disease: pathophysiological and therapeutic implications (review). Mol Med Rep 6: 915–922. - PubMed
1. Do DP, Dowd JB, Ranjit N, House JS, Kaplan GA (2010) Hopelessness, depression, and early markers of endothelial dysfunction in U.S. adults. Psychosom Med 72: 613–619. - PMC - PubMed
1. Severus WE, Littman AB, Stoll AL (2001) Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry 9: 280–293. - PubMed

Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials - PubMed (original) (raw)